大麻效力与精神心理疾病及成瘾的系统综述
该研究为首个大麻效力与精神健康及成瘾关联的系统综述,检索Embase、PsycINFO和MEDLINE至2021年1月14日,纳入20项观察性研究。总体而言,与低效力大麻相比,使用较高效力大麻与精神病和CUD风险增加相关,而抑郁和焦虑的证据不一。
要点
- 较高效力大麻较低效力大麻与精神病风险增加相关。
- 较高效力大麻较低效力大麻与CUD风险增加相关。
- 大麻效力与抑郁和焦虑的关联证据不一。
核心结论
- 较高效力大麻较低效力大麻与精神病和CUD风险增加相关,抑郁和焦虑证据不一。
研究设计与样本
- 系统综述,检索Embase、PsycINFO和MEDLINE从建库至2021年1月14日,筛选4171篇文献,纳入20项观察性研究。
主要发现
- 20项研究中,8项关注精神病,8项关注焦虑,7项关注抑郁,6项关注CUD。
- 较高效力大麻较低效力大麻与精神病风险增加相关。
- 较高效力大麻较低效力大麻与CUD风险增加相关。
- 大麻效力与抑郁和焦虑的关联证据不一。
临床怎么用
- 大麻效力与CUD和精神病风险的关联在医疗保健环境及大麻销售公共卫生指南和政策中具有相关性。
局限性
- 需要标准化暴露测量和纵向设计以加强该关联的证据强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from database inception to Jan 14, 2021). Included studies were observational studies of human participants comparing the association of high-potency cannabis (products with a higher concentration of THC) and low-potency cannabis (products with a lower concentration of THC), as defined by the studies included, with depression, anxiety, psychosis, or cannabis use disorder (CUD). Of 4171 articles screened, 20 met the eligibility criteria: eight studies focused on psychosis, eight on anxiety, seven on depression, and six on CUD. Overall, use of higher potency cannabis, relative to lower potency cannabis, was associated with an increased risk of psychosis and CUD. Evidence varied for depression and anxiety. The association of cannabis potency with CUD and psychosis highlights its relevance in health-care settings, and for public health guidelines and policies on cannabis sales. Standardisation of exposure measures and longitudinal designs are needed to strengthen the evidence of this association.
引用
- Petrilli K, Ofori S, Hines L, et al. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022. PMID: 35901795. doi:10.1016/S2215-0366(22)00161-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。